Skip to main content

Newly Prequalified Active Pharmaceutical Ingredients (APIs)

News
7 December, 2016 - 01:00 (CET)
M

Cycloserine manufactured by Zhejiang Hisun Pharmaceutical Co Ltd and Zinc (sulfate) manufactured by Canton Laboratories Pvt Ltd have been prequalified by the WHO Prequalification Team: medicines (PQTm) under its API prequalification procedure.

  • WHOAPI-262 - Cycloserine - Zhejiang Hisun Pharmaceutical  Co Ltd - CHINA

    • FPPs containing cycloserine are used in the therapeutic area of tuberculosis

 

  • WHOAPI-146 - Zinc (sulfate) - Canton Laboratories Pvt Ltd - INDIA 

    • FPPs containing Zinc (sulfate) are used in the therapeutic area of diarrhoea

Good-quality APIs are vital to the production of good-quality medicines. WHO prequalification of APIs will facilitate production of quality medicines by identifying such APIs for use by manufacturers of finished pharmaceutical products (FPPs).

API prequalification consists of a comprehensive evaluation procedure that has two components: assessment of the API master file (APIMF) to verify compliance with WHO norms and standards, and evaluation of the sites of API manufacture to verify compliance with WHO GMP requirements.